PA
PRME icon

Profund Advisors’s Prime Medicine PRME Stock Holding History

Profund Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$333K Buy
95,806
+26,201
+38% +$99.7K 0.01% 689
2025
Q4 		$242K Buy
+69,605
New +$310K 0.01% 1036
2023
Q4 		– Sell
-21,995
Closed -$210K – 1152
2023
Q3 		$210K Buy
+21,995
New +$286K 0.01% 868

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Profund Advisors's PRME Position: Q1 2026 in Review

Profund Advisors increased its Prime Medicine (PRME) stake by 38% in Q1 2026, buying an estimated $99.7K and bringing the position to 95,806 shares worth $333K. The position accounts for 0.01% of the portfolio, ranked #689.

Profund Advisors first reported a position in PRME in Q3 2023 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Profund Advisors held 95,806 shares of Prime Medicine worth $333K as of Q1 2026.
  • Profund Advisors bought 26,201 Prime Medicine shares in Q1 2026, an estimated $99.7K.
  • Prime Medicine made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #689 holding.
  • Profund Advisors first reported a position in Prime Medicine in Q3 2023 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.